Joe Morgan, MD
Vascular Surgery · Albany, GANPI 1427230150
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,603 of the $6,098 with a category attached, or 75.5%. 32 manufacturers reported payments, led by Silk Road Medical, Inc. at 29.9% of the total. Reporting peaked in 2024 at $2,388 and has fallen 79.0% since, to $501 in 2025. That places this record below the midpoint for vascular surgery clinicians in GA, where the typical reported total is $5,638.
Across 194 payments — averaging $31.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Silk Road Medical, Inc.$2K
- Bard Peripheral Vascular, Inc.$947
- Cardiovascular Systems Inc.$500
- Organogenesis Inc.$352
- Boston Scientific$293
- Vanda Pharmaceuticals Inc.$255
- plus $2K from 26 others
What the payments were for
- Travel & lodging$1,48024%
- Food & beverage$4,60375%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Silk Road Medical, Inc. | 7 | $1,826 |
| Bard Peripheral Vascular, Inc. | 19 | $947 |
| Cardiovascular Systems Inc. | 37 | $500 |
| Organogenesis Inc. | 21 | $352 |
| Boston Scientific | 9 | $293 |
| Vanda Pharmaceuticals Inc. | 11 | $255 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $252 |
| Johnson & Johnson | 17 | $229 |
| Inari Medical, Inc. | 9 | $226 |
| Endologix LLC | 1 | $217 |
| Abbott | 10 | $183 |
| Medtronic | 5 | $103 |
| Kerecis Limited | 4 | $100 |
| Smith+Nephew | 3 | $61 |
| Philips North America LLC | 2 | $55 |
| E.r. Squibb & Sons, L.L.C. | 4 | $52 |
| Paratek Pharmaceuticals, Inc. | 3 | $50 |
| Supernus Pharmaceuticals, Inc. | 2 | $47 |
| Bioxcel Therapeutics, Inc. | 1 | $43 |
| Cordis US CORP. | 2 | $41 |
| Ironshore Pharmaceuticals Inc. | 2 | $38 |
| Lemaitre Vascular, Inc. | 2 | $37 |
| Globus Medical | 1 | $32 |
| Baxter Healthcare | 1 | $26 |
| Angiodynamics, Inc. | 1 | $22 |
| Stryker | 1 | $21 |
| Penumbra, Inc. | 1 | $17 |
| Neuros Medical, Inc. | 1 | $16 |
| Osiris Therapeutics Inc. | 1 | $15 |
| W. L. Gore & Associates, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Cashflow Solutions, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,098 in reported general payments places this provider in the 50th percentile of 176 vascular surgery providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 445 | $263,068 |
| SantylCollagenase Clostridium Hist. | 27 | $12,546 |
| EliquisApixaban | 22 | $12,508 |
| ClopidogrelClopidogrel Bisulfate | 431 | $2,339 |
| Rosuvastatin Calcium | 266 | $1,820 |
| Gabapentin | 124 | $1,140 |
| Atorvastatin Calcium | 140 | $998 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 71 | $907 |
| Cilostazol | 83 | $845 |
| Ezetimibe | 43 | $410 |
| Doxycycline Hyclate | 29 | $339 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 91 | $331 |
| Clindamycin Hcl | 34 | $329 |
| Simvastatin | 32 | $329 |
| Ketoconazole | 12 | $220 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $229 | $263,068445 claims |
| Smith+NephewSantyl | $61 | $12,54627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 176 vascular surgery providers in Georgia.
Other vascular surgery in Albany
- Daniel MartinAlbany$38K
- Siddharth PatelAtlanta$303K
- Juan AyerdiColumbus$130K
- Albert RichardsonThomasville$103K
- Walaya Methodius-RayfordAtlanta$79K
- Eric MartinFort Gordon$64K
- William JordanAugusta$64K
- Alykhan LalaniMarietta$64K
- Charles MoomeyGainesville$52K
- Suman AnnambhotlaGainesville$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.